These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6751302)

  • 1. Intrathecal interferon in multiple sclerosis.
    Jacobs L; O'Malley J; Freeman A; Murawski J; Ekes R
    Arch Neurol; 1982 Oct; 39(10):609-15. PubMed ID: 6751302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal interferon reduces exacerbations of multiple sclerosis.
    Jacobs L; O'Malley J; Freeman A; Ekes R
    Science; 1981 Nov; 214(4524):1026-8. PubMed ID: 6171035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal interferon in the treatment of multiple sclerosis. Patient follow-up.
    Jacobs L; O'Malley JA; Freeman A; Ekes R; Reese PA
    Arch Neurol; 1985 Sep; 42(9):841-7. PubMed ID: 4026626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Josefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Lancet; 1986 Dec 20-27; 2(8521-22):1411-3. PubMed ID: 2878272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Jozefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Arch Neurol; 1987 Jun; 44(6):589-95. PubMed ID: 3579676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic alpha-interferon therapy of multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CK; Kamin-Lewis RM; Johnson KP
    Neurology; 1984 Oct; 34(10):1273-9. PubMed ID: 6384817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.
    Milanese C; Salmaggi A; La Mantia L; Campi A; Eoli M; Savoiardo M; Bianchi G; Nespolo A
    J Neurol Neurosurg Psychiatry; 1990 Jul; 53(7):554-7. PubMed ID: 1697334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less drug fever with intrathecally applied interferon-beta (short communication).
    Westarp ME; Hülser PJ; Westphal KP; Wollinsky KH; Kornhuber HH
    Int J Clin Pharmacol Ther Toxicol; 1991 Feb; 29(2):71-4. PubMed ID: 2026467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
    Camenga DL; Johnson KP; Alter M; Engelhardt CD; Fishman PS; Greenstein JI; Haley AS; Hirsch RL; Kleiner JE; Kofie VY
    Arch Neurol; 1986 Dec; 43(12):1239-46. PubMed ID: 3535752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal interferon as treatment of multiple sclerosis. A planned multicenter study.
    Jacobs L; O'Malley JA; Freeman A; Reese P
    Arch Neurol; 1983 Oct; 40(11):683-6. PubMed ID: 6354150
    [No Abstract]   [Full Text] [Related]  

  • 11. Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis.
    Mora JS; Munsat TL; Kao KP; Finison LJ; Hedlund W; Bradley GA; Scheife R; Georgiades JA
    Neurology; 1986 Aug; 36(8):1137-40. PubMed ID: 3526180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecal beta-interferon in multiple sclerosis.
    Milanese C; Salmaggi A; la Mantia L; Corridori F; Nespolo A
    Lancet; 1988 Sep; 2(8610):563-4. PubMed ID: 2900935
    [No Abstract]   [Full Text] [Related]  

  • 13. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta for multiple sclerosis.
    Connelly JF
    Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH
    Mult Scler; 1995 Jun; 1(2):118-35. PubMed ID: 9345462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
    Axelsson M; Mattsson N; Malmeström C; Zetterberg H; Lycke J
    J Neuroimmunol; 2013 Nov; 264(1-2):100-5. PubMed ID: 24125567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha interferon clinical trial for multiple sclerosis: design considerations.
    Alter M; Greenstein J; Camenga D; LaRue L
    Neuroepidemiology; 1987; 6(1-2):85-92. PubMed ID: 3306431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon.
    Confavreux C; Chapuis-Cellier C; Arnaud P; Robert O; Aimard G; Devic M
    J Neurol Neurosurg Psychiatry; 1986 Nov; 49(11):1308-12. PubMed ID: 3794738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings.
    Huber M; Bamborschke S; Assheuer J; Heiss WD
    J Neurol; 1988 Jan; 235(3):171-3. PubMed ID: 3367166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.